Inhibition of heat-shock protein 90 reduces Ebola virus replication

Antiviral Research

Volumn 87, Issue 2, 2010, Pages 187-194

  Smith, Darci R ^a   McCarthy, Sarah ^a   Chrovian, Andrew ^a   Olinger, Gene ^a   Stossel, Andrea ^a   Geisbert, Thomas W ^b   Hensley, Lisa E ^a   Connor, John H ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ebola virus; Hsp90; Therapeutic

Indexed keywords

GELDANAMYCIN; RADICICOL; TANESPIMYCIN; ANTIVIRUS AGENT; BENZOQUINONE DERIVATIVE; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; MACROLIDE; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EBOLA VIRUS; HUMAN; HUMAN CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; HOST PATHOGEN INTERACTION; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERO CELL LINE; VIRAL PLAQUE ASSAY;

ANIMALS; ANTIVIRAL AGENTS; BENZOQUINONES; CERCOPITHECUS AETHIOPS; EBOLAVIRUS; ENZYME INHIBITORS; HOST-PATHOGEN INTERACTIONS; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PLAQUE ASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VERO CELLS; VIRUS REPLICATION; VIRAL PLAQUE ASSAY;

EBOLA VIRUS; FILOVIRIDAE; PRIMATES; RNA VIRUSES;

EID: 77954951982     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.04.015     Document Type: Article

References (39)

1. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 2009, 15(1):9-14.
2. Barta T.E., Veal J.M., Rice J.W., Partridge J.M., Fadden R.P., Ma W., Jenks M., Geng L., Hanson G.J., Huang K.H., Barabasz A.F., Foley B.E., Otto J., Hall S.E. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg. Med. Chem. Lett. 2008, 18(12):3517-3521.
3. Burch A.D., Weller S.K. Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J. Virol. 2005, 79(16):10740-10749.
4. Chase G., Deng T., Fodor E., Leung B.W., Mayer D., Schwemmle M., Brownlee G. Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 2008, 377(2):431-439.
5. Clevenger R.C., Blagg B.S. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org. Lett. 2004, 6(24):4459-4462.
6. Connor J.H., McKenzie M.O., Parks G.D., Lyles D.S. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 2007, 362(1):109-119.
7. Das T., Mathur M., Gupta A.K., Janssen G.M., Banerjee A.K. RNA polymerase of vesicular stomatitis virus specifically associates with translation elongation factor-1 alphabetagamma for its activity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(4):1449-1454.
8. Delmotte P., Delmotte-Plaque J. A new antifungal substance of fungal origin. Nature 1953, 171(4347):344.
9. Geisbert T.W., Hensley L.E., Larsen T., Young H.A., Reed D.S., Geisbert J.B., Scott D.P., Kagan E., Jahrling P.B., Davis K.J. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 2003, 163(6):2347-2370.
10. Geller R., Vignuzzi M., Andino R., Frydman J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 2007, 21(2):195-205.
11. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23(6):1078-1087.
12. Gupta A.K., Shaji D., Banerjee A.K. Identification of a novel tripartite complex involved in replication of vesicular stomatitis virus genome RNA. J. Virol. 2003, 77(1):732-738.
13. Hu J., Flores D., Toft D., Wang X., Nguyen D. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J. Virol. 2004, 78(23):13122-13131.
14. Hu J., Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(3):1060-1064.
15. Hu J., Toft D.O., Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J. 1997, 16(1):59-68.
16. Huang K.H., Veal J.M., Fadden R.P., Rice J.W., Eaves J., Strachan J.P., Barabasz A.F., Foley B.E., Barta T.E., Ma W., Silinski M.A., Hu M., Partridge J.M., Scott A., DuBois L.G., Freed T., Steed P.M., Ommen A.J., Smith E.D., Hughes P.F., Woodward A.R., Hanson G.J., McCall W.S., Markworth C.J., Hinkley L., Jenks M., Geng L., Lewis M., Otto J., Pronk B., Verleysen K., Hall S.E. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J. Med. Chem. 2009, 52(14):4288-4305.
17. Hung J.J., Chung C.S., Chang W. Molecular chaperone Hsp90 is important for vaccinia virus growth in cells. J. Virol. 2002, 76(3):1379-1390.
18. Johnson K.M., Lange J.V., Webb P.A., Murphy F.A. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1977, 1(8011):569-571.
19. Kampmueller K.M., Miller D.J. The cellular chaperone heat shock protein 90 facilitates Flock House virus RNA replication in Drosophila cells. J. Virol. 2005, 79(11):6827-6837.
20. Li Y.H., Tao P.Z., Liu Y.Z., Jiang J.D. Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro. Antimicrob. Agents Chemother. 2004, 48(3):867-872.
21. Momose F., Naito T., Yano K., Sugimoto S., Morikawa Y., Nagata K. Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J. Biol. Chem. 2002, 277(47):45306-45314.
22. Naito T., Momose F., Kawaguchi A., Nagata K. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J. Virol. 2007, 81(3):1339-1349.
23. Nakagawa S., Umehara T., Matsuda C., Kuge S., Sudoh M., Kohara M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem. Biophys. Res. Commun. 2007, 353(4):882-888.
24. Pearl L.H., Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75:271-294.
25. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 2003, 228(2):111-133.
26. Putcha P., Danzer K.M., Kranich L., Scott A., Silinski M., Mabbett S., Hicks C.D., Veal J.M., Steed P.M., Hyman B.T., McLean P.J. Brain permeable small molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 2009.
27. Rice J.W., Veal J.M., Fadden R.P., Barabasz A.F., Partridge J.M., Barta T.E., Dubois L.G., Huang K.H., Mabbett S.R., Silinski M.A., Steed P.M., Hall S.E. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008, 58(12):3765-3775.
28. Richter K., Buchner J. Hsp90: chaperoning signal transduction. J. Cell. Physiol. 2001, 188(3):281-290.
29. Sanchez A., Khan A.S., Zaki S.R., Nabel G.J., Ksiazek T., Peters C.J. Filoviridae: Marburg and Ebola viruses. Fields Virology 2001, vol. 1:1279-1304. Lippincott Williams & Wilkins, New York.
30. Shen X., Masters P.S. Evaluation of the role of heterogeneous nuclear ribonucleoprotein A1 as a host factor in murine coronavirus discontinuous transcription and genome replication. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(5):2717-2722.
31. Stahl M., Retzlaff M., Nassal M., Beck J. Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system. Nucleic Acids Res. 2007, 35(18):6124-6136.
32. Strauss J.H., Strauss E.G. Viral RNA replication. With a little help from the host. Science 1999, 283(5403):802-804.
33. Taldone T., Sun W., Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. 2009, 17(6):2225-2235.
34. Towner J.S., Paragas J., Dover J.E., Gupta M., Goldsmith C.S., Huggins J.W., Nichol S.T. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 2005, 332(1):20-27.
35. Ujino S., Yamaguchi S., Shimotohno K., Takaku H. Heat-shock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3. J. Biol. Chem. 2009, 284(11):6841-6846.
36. Waxman L., Whitney M., Pollok B.A., Kuo L.C., Darke P.L. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(24):13931-13935.
37. Weidmann M., Muhlberger E., Hufert F.T. Rapid detection protocol for filoviruses. J. Clin. Virol. 2004, 30(1):94-99.
38. Whelan S.P., Barr J.N., Wertz G.W. Transcription and replication of nonsegmented negative-strand RNA viruses. Curr. Top. Microbiol. Immunol. 2004, 283:61-119.
39. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5(10):761-772.